How I treat newly diagnosed acute lymphoblastic leukemia
Clinical Hematology International · 09.05.2024 · 6 (2)
DOI: 10.46989/001c.117026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International, online erschienen am 09.05.2024. Verfasst von Giebel Sebastian. Beteiligte Einrichtung: Bone Marrow Transplantation and Onco-Hematology Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph- ALL intensive induction-consolidation chemotherapy using “pediatric-inspired” protocols is a standard of care. Allogeneic hematopoietic cell transplantation (allo-HCT) from either an HLA-matched sibling, unrelated or haploidentical donor should be considered for patients with high estimated risk of relapse. Inadequate response at the level of measurable residual disease (MRD) is the strongest adverse prognostic factor. Patients with B-ALL and detectable MRD should be treated with blinatumomab. In the future, the use of blinatumomab and/or inotuzumab ozogamycin in addition to first-line chemotherapy may become a new standard of care reducing the role of allo-HCT. For patients with Ph+ ALL, tyrosine kinase inhibitors (TKI) are the most important components of treatment protocols, while the intensity of chemotherapy may be reduced. Allo-HCT is recommended for all patients treated with imatinib along with low-intensity chemotherapy. Results of phase-II studies using front-line dasatinib or ponatinib in sequence or in combination with blinatumomab are very promising. Such a strategy may allow the avoidance of systemic chemotherapy. The future role of allo-HCT in this context appears uncertain.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bone Marrow Transplantation and Onco-Hematology Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch.
ORCID-Profile: Giebel Sebastian
Zitieren
APA
Sebastian, G. (2024). How I treat newly diagnosed acute lymphoblastic leukemia. Clinical Hematology International, 6(2). https://doi.org/10.46989/001c.117026
Vancouver
Sebastian G. How I treat newly diagnosed acute lymphoblastic leukemia. Clinical Hematology International. 2024;6(2). doi:10.46989/001c.117026
BibTeX
@article{Sebastian2024,
author = {Sebastian, Giebel},
title = {How I treat newly diagnosed acute lymphoblastic leukemia},
journal = {Clinical Hematology International},
year = {2024},
volume = {6},
number = {2},
doi = {10.46989/001c.117026}
}
EUVIMED